结肠直肠癌B7S1表达与免疫浸润的关系

外科理论与实践››2021,Vol. 26››Issue (04): 336-342.doi:10.16139/j.1007-9610.2021.04.011

结肠直肠癌B7S1表达与免疫浸润的关系

王常刚¹, 刘坤¹, 冯浩然¹, 蒋奕玫¹, 施毅卿¹, 陈献则¹, 宋子甲¹, 李军¹, 李佑¹, 蔡东莉³, 赵任¹^,²()

1.开云网页登录医学院附属瑞金医院（北部院区）普外科,上海 201800
2.开云网页登录医学院附属瑞金医院外科, 上海 200025
3.同济大学附属上海市第一妇婴保健院;临床转化医学研究中心,上海 200011

收稿日期:2021-04-19出版日期:2021-07-25发布日期:2022-08-02
通讯作者:赵任 E-mail:rjzhaoren@139.com
基金资助:
上海市卫生健康委员会卫生行业临床研究专项(20204Y0006);开云网页登录医学院附属瑞金医院北院研究基金(2018ZY15)

Expression of B7S1 related with immune infiltration in colorectal cancer

WANG Changgang¹, LIU Kun¹, FENG Haoran¹, JIANG Yimei¹, SHI Yiqing¹, CHEN Xianze¹, SONG Zijia¹, LI Jun¹, LI You¹, CAI Dongli³, ZHAO Ren¹^,²()

1. Department of General Surgery, Ruijin Hospital（North）, Shanghai Jiao Tong University School of Medicine, Shanghai 201800, China
2. Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
3. Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University, Shanghai, 200011, China

Received:2021-04-19Online:2021-07-25Published:2022-08-02
Contact:ZHAO Ren E-mail:rjzhaoren@139.com

摘要/Abstract

摘要：

目的：探讨B7S1（由VTCN1 编码）mRNA水平及蛋白质水平在结肠直肠癌（colorectal cancer,CRC）中的表达,分析其与临床病理特征、免疫细胞浸润以及预后的相关性,评估其作为CRC免疫治疗靶点的潜在应用价值。方法：利用Oncomine及TIMER数据库检索VTCN1在人体多种实体瘤中的表达。利用UALCAN及LinkedOmics数据库分析VTCN1表达量与CRC临床病理特征的关系。利用人类蛋白质图谱、Kaplan-Meier Plotter和TIMER数据库分析评估CRC中VTCN1表达量与免疫细胞浸润及临床预后的相关性。收集瑞金医院（北部院区）24例CRC病人,利用免疫荧光染色技术检测B7S1蛋白水平在CRC和正常肠道组织中的表达。结果：通过数据库发现 VTCN1在人体多种实体肿瘤中表达。与正常肠道组织对比,VTCN1在CRC的多种亚型中均高表达。上调表达的VTCN1与肿瘤分期、淋巴结转移、远处转移、错配修复状态及总生存率相关。VTCN1与免疫细胞浸润存在一定的相关性。免疫荧光染色结果显示,相较于正常肠道组织,B7S1蛋白水平在CRC中上调表达。在CD45^-细胞及CD45⁺免疫细胞中均有表达。结论：B7S1作为共抑制性免疫检查点分子,可能成为CRC潜在的预后因子或免疫治疗靶点。

关键词:结肠直肠癌,B7S1,免疫检查点,免疫微环境,肿瘤浸润淋巴细胞

Abstract:

ObjectiveTo investigate the expression of B7S1 mRNA which is encoded by VTCN1 and protein levels in colorectal cancer(CRC) with the analysis of relation to clinicopathological characteristics, immune cell infiltration, and prognosis for the evaluation as a immunotherapeutic target in CRC.MethodsBoth Oncomine and TIMER databases were used to review the expression of VTCN1 in a variety of human solid tumors. The relationship between the expression of VTCN1 and the clinicopathological characteristics of CRC was analyzed using UALCAN and LinkedOmics databases. The expression of VTCN1 which is related with immune infiltration and clinical prognosis was evaluated using Human Protein Atlas database, Kaplan-Meier Plotter and TIMER database. A total of 24 patients with CRC in Ruijin Hospital (North) were collected and the expression of B7S1 protein in both CRC and normal intestinal tissues was detected by immunofluorescence staining.ResultsIt was found in database that VTCN1 was expressed in many human solid tumors. VTCN1 was highly expressed in various subtypes of CRC when compared with that in normal intestinal tissues. The up-regulated VTCN1 was related to tumor stage, lymph node metastasis, distant metastasis, mismatch repair and overall survival rate. VTCN1 was also related to the immune cell infiltration. Immunofluorescence analysis showed that the protein of B7S1 was up-regulated in CRC when compared with that in normal intestinal tissues, and it was expressed in CD45^-cells and CD45⁺cells.ConclusionsAs co-inhibitory immune checkpoint molecule, B7S1 may be a potential prognostic factor and might become the target of immunotherapy for CRC.

Key words:Colorectal cancer,B7S1,Immune checkpoint,Immune microenvironment,Tumor-infiltrating lymphocyte

中图分类号:

王常刚, 刘坤, 冯浩然, 蒋奕玫, 施毅卿, 陈献则, 宋子甲, 李军, 李佑, 蔡东莉, 赵任. 结肠直肠癌B7S1表达与免疫浸润的关系[J]. 外科理论与实践, 2021, 26(04): 336-342.

WANG Changgang, LIU Kun, FENG Haoran, JIANG Yimei, SHI Yiqing, CHEN Xianze, SONG Zijia, LI Jun, LI You, CAI Dongli, ZHAO Ren. Expression of B7S1 related with immune infiltration in colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 336-342.

图/表8

图1

CRC类型	P值	t	差异倍数	%	样本
结肠黏液腺癌	6.91×10^-7	6.075	3.632	11	44
直肠腺癌	4.56×10^-10	7.263	2.333	12	82
直肠黏液腺癌	0.001	5.184	4.913	12	28
盲肠腺癌	7.40×10^-7	6.222	5.193	13	44
结肠腺癌	1.34×10^-9	6.627	2.392	14	123
直肠乙状结肠腺癌	0.019	4.422	4.572	20	25

表1

图2

图3

图4

图5

图6

图7

参考文献13

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi:10.3322/caac.21492 URL
[2]	Xie S, Huang J, Qiao Q, et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors[J]. Cancer Immunol Immunother, 2018, 67(11):1685-1694. doi:10.1007/s00262-018-2227-8 URL
[3]	Overman MJ, Lonardi S, Wong KYM, et al. Durable cli-nical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8):773-779.
[4]	Tang J, Jiang W, Liu D, et al. The comprehensive mole-cular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability[J]. Oncoimmunology, 2018, 7(10):e1488566.
[5]	Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer[J]. Semin Cancer Biol, 2018, 52(Pt 2):189-197. doi:10.1016/j.semcancer.2018.02.010 URL
[6]	Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3):434-452. doi:10.1016/j.immuni.2018.03.014 URL
[7]	Sharpe AH, Freeman GJ. The B7-CD28 superfamily[J]. Nat Rev Immunol, 2002, 2(2):116-126. doi:10.1038/nri727 URL
[8]	Cai D, Li J, Liu D, et al. Tumor-expressed B7-H3 media-tes the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy[J]. Cell Mol Immunol, 2020, 17(3):227-236. doi:10.1038/s41423-019-0305-2 URL
[9]	Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6):361-375. doi:10.1038/s41575-019-0126-x URL
[10]	Lee JJ, Chu E. Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2018, 17(4):258-273. doi:10.1016/j.clcc.2018.06.004 URL
[11]	Flem-Karlsen K, Fodstad Ø, Nunes-Xavier CE. B7-H3 immune checkpoint protein in human cancer[J]. Curr Med Chem, 2020, 27(24):4062-4086. doi:10.2174/0929867326666190517115515pmid:31099317
[12]	Li J, Lee Y, Li Y, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8(+) T cells[J]. Immunity, 2018, 48(4):773-786. doi:10.1016/j.immuni.2018.03.018 URL
[13]	Prasad DV, Richards S, Mai XM, et al. B7S1, a novel B7 family member that negatively regulates T cell activation[J]. Immunity, 2003, 18(6):863-873. doi:10.1016/S1074-7613(03)00147-X URL

[1]	韩序, 王文权, 楼文晖, 刘亮.免疫检查点抑制剂治疗胃肠胰神经内分泌肿瘤的进展[J]. 外科理论与实践, 2023, 28(03): 267-272.
[2]	殷剑光, 宗雅萍, 沈晓卉, 赵敬坤, 陆爱国.同时性多原发结肠直肠癌治疗与预后分析（附39例报告）[J]. 外科理论与实践, 2022, 27(06): 540-544.
[3]	包全, 邢宝才.复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130.
[4]	于颖彦.免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(01): 48-52.
[5]	宗春燕，沈键锋.免疫治疗能否治愈肿瘤？[J]. 开云网页登录学报, 2021, 55(Sup.1): 53-54.
[6]	刘诗光, 赵敬坤, 陆爱国, 毛志海.趋化因子CXCL5和程序性死亡配体 1在结肠直肠癌组织的表达与病人预后的关系[J]. 外科理论与实践, 2021, 26(06): 543-549.
[7]	张华, 陆炜, 杨承翌, 项明洁.血清人衰老关键蛋白1检测对结肠直肠癌的诊断和预后价值[J]. 诊断学理论与实践, 2021, 20(05): 462-465.
[8]	顾卫琼.免疫检查点抑制剂致甲状腺损伤的诊治进展[J]. 诊断学理论与实践, 2021, 20(04): 338-342.
[9]	王晓斐, 张秋蕊.免疫检查点抑制剂致肺部不良反应的诊治进展[J]. 诊断学理论与实践, 2021, 20(04): 343-348.
[10]	周艺, 杨莉.粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021, 20(04): 407-413.
[11]	茅届齐, 徐多刚, 张米粒, 肖蕴誉, 明旭, 李雨哲, 曹灿, 于亮, 李继坤.结肠直肠癌病人D-二聚体升高的研究[J]. 外科理论与实践, 2021, 26(04): 361-366.
[12]	蔡三军.结肠直肠癌诊治的思考[J]. 外科理论与实践, 2021, 26(04): 297-299.
[13]	张弢, 叶枫, 赵任.结肠直肠癌的微创手术——在工具和价值间的不断平衡优化[J]. 外科理论与实践, 2021, 26(04): 300-304.
[14]	杨飖, 傅传刚.NOSES在结肠直肠癌手术中的应用现状与展望[J]. 外科理论与实践, 2021, 26(04): 305-311.
[15]	杨盈赤, 宋建宁, 张忠涛.中国腹腔镜结肠直肠手术的回顾与展望——基于手术病例登记研究和数据库建立的思考[J]. 外科理论与实践, 2021, 26(04): 277-280.